Mr Chong Weng Hoe, Non-Executive Chairman and Independent Director
Mr. Chong Weng Hoe was appointed Independent Non-executive Director of the Company on 1 July 2021. Mr. Chong is currently the Executive Vice President of TÜV SÜD Asia Pacific Pte. Ltd., a position he has held since 2016, where he oversees a global network of wireless laboratories. He has held numerous positions within TÜV SÜD PSB Pte. Ltd. since 1991 where he joined as an engineer and was subsequently promoted to vice president, senior vice president, chief executive officer and then a director of the board. Mr. Chong is presently also independent director of Keong Hong Holdings Limited, listed on the mainboard of the SGX-ST as well as independent director of HC Surgical Specialist Limited and Singapore Paincare Holdings Ltd, both of which are listed on Catalist.
Mr. Chong graduated from the National University of Singapore with a Bachelor of Engineering (Electrical) in 1989 and obtained a Master of Business Administration (Accountancy) from Nanyang Technological University in 1997.
Dr Lee Hung Ming, Executive Vice-Chairman
Dr Lee Hung Ming is our Executive Vice Chairman, an ex-officio member of our Medical Board and Centre Director of Lee Hung Ming Eye Centre since 2007.
Dr Lee is a Senior Consultant Ophthalmologist, currently spearheading Lee Hung Ming Eye Centre (formerly known as Parkway Eye Centre) at Gleneagles Hospital. He is a renowned LASIK and cataract specialist and is considered a key opinion leader in his fields of subspecialty, namely cornea, refractive surgery, external eye disease, cataract and implant surgery. Dr Lee held the position of Senior Consultant for Cataract, Cornea & Refractive Surgery Service at The Eye Institute, National Group, Singapore, which he joined in 2003. Dr Lee currently also sits on the Asia Refractive Council of Bausch & Lomb.
Between 2002 and 2007, he was also Clinical Director of the LASIK Centre of the National University Hospital.
From 2000 to 2007, Dr Lee was appointed as Head & Senior Consultant in Tan Tock Seng Hospital, Refractive Surgery.
He completed his residency in ophthalmology at Tan Tock Seng Hospital and the Singapore National Eye Centre, and completed a clinical fellowship in Cornea, External Eye Disease and Refractive Surgery at the University of Toronto.
He has sat on board of various professional associations, such as the College of Ophthalmologists, Surgeons and Singapore Society of Ophthalmologist and Bausch & Lomb’s Asia Refractive Council. He has also been the examiner for the specialist post-graduate examination by the National University of Singapore and the Royal College of Surgeons, Edinburgh (UK), University Sains Malaysia and University Malaya. He was also visiting professor at University Sains Malaysia. Dr Lee has also presented widely at regional and international ophthalmology conferences.
Dr Lee has received various awards, including the A.C.E. Award (APSCRS Certified Educator Award) in 2003 for excellence in training and education of eye surgeons in the Asia Pacific region by the Asia Pacific Society of Cataract and Refractive Surgery, the International Gold Medal in 2011 by the Indian Intraocular Implant and Refractive Society for outstanding contribution in the field of ophthalmology, as well as the University of Toronto John Gaby Research Prize. Dr Lee is a licensed medical practitioner in Singapore, the United Kingdom and Canada. He is a member of the Chapter of Ophthalmologist at the Academy of Medicine, Singapore.
Dr Lee graduated from the National University of Singapore with a Bachelor of Medicine and Bachelor of Surgery in 1989 and subsequently obtained his Master of Medicine in Ophthalmology from the Graduate School of Medical Studies, National University of Singapore, FRCS from the Royal College of Edinburgh Scotland and FAMS (Ophth) from the Academy of Medicine, Singapore.
Ms Wee Kim Lin Evelyn, Non-Executive and Independent Director
Ms Evelyn Wee was appointed Independent Non-executive Director of the Company on 1 May 2024.
Ms Wee is currently the Deputy Head of the Corporate and Transactional Group of Rajah & Tann Singapore LLP. She also heads R&T’s Capital Markets Practice and is a senior partner with the Mergers & Acquisitions Practice. She has more than 30 years of experience in mergers and acquisitions, private equity / venture capital investments and capital markets transactions. She regularly advises, inter alia, listed vehicles on their corporate/compliance matters and clients on cross border transactions, which include investments in, and divestments of, businesses and assets in South Asia, Southeast Asia, Europe and South America.
Ms Wee has been recognised as a leading / recommended lawyer in major ranking publications such as Chambers Asia-Pacific – Capital Markets: Domestic and Chambers Global, IFLR1000 in Capital Markets and M&A, The Legal 500 Asia-Pacific in Capital Markets / M&A, Best Lawyers, Who’s Who Legal and Asialaw. She was most recently recognised as Dealmaker of the Year at the Asian Legal Business SE Asia Law Awards 2024 and Equity Capital Markets Lawyer of the Year at the Women in Business Law Awards 2023 Asia-Pacific, and was also named as one of the “Dealmakers of Asia 2022 and 2023” by Asian Legal Business.
Ms Wee graduated from the National University of Singapore in 1989 and was admitted to the Singapore Bar in March 1990 and to the Roll of Solicitors of England and Wales in 1998. She is also an Accredited Mediator of the Singapore International Mediation Institute.
Mr Chen Bang, Non-Executive and Non-Independent Director
Mr Chen Bang was appointed to the Board of as a Non-Executive and Non-Independent Director on 27 December 2019.
Mr Chen is seeking re-election pursuant to Article 118 of the Company’s constitution and the additional information required under Appendix 7F – Announcement of Appointment of the Catalist Rules are set out in this profile. The re-election of Mr Chen as Non-Executive and Non-Independent Director was recommended by the Nominating Committee and approved
by the Board, after taking into consideration his qualifications, expertise and past experiences.
Mr Chen is a director of a substantial shareholder of the Company, Aier Eye International (Singapore) Pte. Ltd..
In relation to Mr Chen’s working experience and occupation, Mr Chen is the Chairman and controlling shareholder of Aier Eye Hospital Group Co., Ltd. (“Aier”) since 2003 whose main business is similar to the Group. As at the date of this Annual Report, Aier Group has no business in Southeast Asia, other than those carried out by our Group.
His country of principal residence is the People’s Republic of China.
Mr Chen has over 20 years of experience in the eye care sector. He co-founded Aier in 2003, and was instrumental in leading it to become the largest eye care group in the world by number of hospitals and by market capitalisation. Aier is listed on the Shenzhen Stock Exchange.
Mr Chen Bang is also the Chairman of Clínica Baviera, S.A. which is a Spain-based company listed on the Madrid Stock Exchange engaged in the healthcare sector and focuses on providing services within the field of ophthalmic medicine.
He has been widely recognised for his entrepreneurship and was awarded “Most Respected Chairman of Chinese Listed Company” in 2011 and 2012 and named “EY Entrepreneur of The Year” in 2014 and “China Most Influential Listed Company Leader” in both 2014 and 2015.
For his philanthropic work, Mr Chen was given the “Hunan Charity Award” in 2015. He graduated from Hunan University with an MBA in 2007.
Mr Li Li, Non-Executive and Non-Independent Director
Mr Li Li was appointed to the Board as our Non-Executive and Non-Independent Director on 25 March 2020.
Mr Li is seeking re-election pursuant to Article 118 of the Company’s Constitution and the additional information required under Appendix 7F of the Catalist Rules are set out in this profile. The re-election of Mr Li as Non-Executive and Non-Independent Director was recommended by the Nominating Committee and approved by the Board, after taking into
consideration his qualifications, expertise and past experiences.
Mr Li was nominated to be appointed as a Director by a substantial shareholder of the Company, Aier Eye International (Singapore) Pte. Ltd..
In relation to Mr Li’s working experience and occupation, Mr Li is the Vice-Chairman of Aier Eye Hospital Group Co., Ltd. (“Aier”) since 2003 whose main business is similar to the Company. As at the date of this Annual Report, Aier Group has no business in Southeast Asia, other than those carried out by our Group.
His country of principal residence is the People’s Republic of China.
Mr Li was one of the co-founders of Aier in 2003 and played a key role in spearheading Aier into the largest eye care group in the world by number of hospitals and market capitalisation. With over 20 years of experience in the eye care sector, he is the Vice-Chairman and CEO of Aier and sits on the Board of Clinica Baviera, S.A., which is a Spain-based company listed on the Madrid Stock Exchange engaged in the healthcare sector and focuses on providing services within the field of ophthalmic medicine.
Mr Li was recognised for his outstanding entrepreneurship and leadership in 2018 with the “Outstanding Entrepreneur Award” by Changsha High-Tech Zone. He is also a strong advocate of education, having established AIER School of Ophthalmology, AIER School of Optometry, AIER Ophthalmology Institute, AIER Institute of Optometry and others, since 2015. He is also the dean of AIER Management School, honorary lifetime supervisor of Eye Care Foundation, Vice Chairman of Chinese nongovernment Medical Institution Association and group leader of Ophthalmic Management.
Ms Zhang Yongmei, Non-Executive and Non-Independent Director
Ms Zhang Yongmei was appointed to Board as a Non-Executive and Non-Independent Director on 27 December 2019.
Ms Zhang is seeking re-election pursuant to Article 118 of the Company’s constitution and the additional information required under Appendix 7F – Announcement of Appointment of the Catalist Rules are set out in this profile. The re-election of Ms Zhang as Non-Executive and Non-Independent Director, and member of the Audit Committee, Nominating Committee
and Remuneration Committee, was recommended by the Nominating Committee and approved by the Board, after taking into consideration her qualifications, expertise and past experiences.
Ms Zhang is a director of a substantial shareholder of the Company, Aier Eye International (Singapore) Pte. Ltd..
Ms Zhang is a member of the management of Aier Eye Hospital Group Co., Ltd. (“Aier”) and its subsidiaries (collectively, the “Aier Group”) whose main business is similar to the Company. As at the date of this Annual Report, Aier Group has no business in Southeast Asia, other than those carried out by our Group.
Her country of principal residence is the People’s Republic of China. Ms Zhang is a non-practising member of The Chinese Institute of Certified Public Accountants (CICPA) and has extensive experience in corporate finance and M&A. She joined Aier Eye Hospital Group Co., Ltd. in 2014 as Global Strategy and Business Development Director. From 2012 to 2014, she
was Corporate Development Senior Manager in Best Buy Corporation and in charge of the development strategy and execution of projects for new ventures. From 2011 to 2012, she was Strategy & Business Development (M&A) Senior Manager and led the M&A team covering the healthcare value chain. From 2007 to 2011, she was Transaction Services & Global Health Senior Manager in PricewaterhouseCoopers and carried out financial due diligence in M&A projects and healthcare strategy advisory.
Ms Zhang is also a director of Clínica Baviera, S.A., which is a Spain-based company listed on the Madrid Stock Exchange engaged in the healthcare sector and focuses on providing services within the field of ophthalmic medicine.
She graduated from Tongji University with a Bachelor of Science degree in 2002 and Fudan University with an MBA in 2013.